This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 6;115(3):222-228.
doi: 10.1093/trstmh/traa170.

Implications of the COVID-19 pandemic in eliminating trachoma as a public health problem

Affiliations

Implications of the COVID-19 pandemic in eliminating trachoma as a public health problem

Seth Blumberg et al. Trans R Soc Trop Med Hyg. .

Abstract

Background: Progress towards elimination of trachoma as a public health problem has been substantial, but the coronavirus disease 2019 (COVID-19) pandemic has disrupted community-based control efforts.

Methods: We use a susceptible-infected model to estimate the impact of delayed distribution of azithromycin treatment on the prevalence of active trachoma.

Results: We identify three distinct scenarios for geographic districts depending on whether the basic reproduction number and the treatment-associated reproduction number are above or below a value of 1. We find that when the basic reproduction number is <1, no significant delays in disease control will be caused. However, when the basic reproduction number is >1, significant delays can occur. In most districts, 1 y of COVID-related delay can be mitigated by a single extra round of mass drug administration. However, supercritical districts require a new paradigm of infection control because the current strategies will not eliminate disease.

Conclusions: If the pandemic can motivate judicious, community-specific implementation of control strategies, global elimination of trachoma as a public health problem could be accelerated.

Keywords: COVID-19; control; elimination; mass drug administration; mathematical modelling; trachoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic of the model. The ‘MDA as planned’ scenario involves periods of exponential growth of prevalence punctuated by uniformly spaced reduction due to annual MDA. The ‘MDA disrupted’ scenario assumes disruption of MDA programs occurs at year 1.0 and includes one missed round of MDA at year 1.5. Infection prevalence represents the proportion of children 1–9 y of age with current infection. Note that infection prevalence is distinct from the clinical manifestation of trachomatous inflammation–follicular. An R0 of 1.5 is assumed. The program delay is the length of MDA disruption. The control delay is the expected delay in trachoma control due to disruption of MDA. The horizontal grey line represents the 0.05 benchmark for trachoma control that aligns with the WHO's active trachoma criterion for elimination of trachoma as a public health problem.
Figure 2.
Figure 2.
Modelling scenarios. Each panel corresponds to a different level of transmission, as defined by whether R0 and RT are >1 or <1 (Table 1). The layout of each panel is similar to Figure 1. Within each panel the ‘MDA as planned’ scenario corresponds to no disruption of annual MDA. The ‘MDA disrupted’ scenario corresponds to a 1-y disruption starting at year 1.0 and includes skipping one annual MDA cycle at year 1.5. The ‘MDA catch-up’ scenario involves giving an extra MDA at year 3 after skipping an annual MDA at year 1.5. Between MDA cycles, the transmission dynamics are determined by a susceptible–infected–susceptible model (see Methods for details). For visual clarity, the time series corresponding to the scenarios are slightly offset horizontally. An R0 of 0.95, 1.5 and 2.5 are assumed for subcritical, MDA-subcritical and supercritical transmission, respectively. At the time of MDA disruption (year 1.0), the infection prevalence of the three transmission scenarios is 0.06, 0.13 and 0.36, respectively. This corresponds to an Reffective of 0.89, 1.30 and 1.61, respectively.
Figure 3.
Figure 3.
Our estimate of the control delay for trachoma is depicted by colour, based on the Reffective of the district and the program delay for the administration of MDA. The underlying model assumes annual MDA leads to a 70% decrease in trachoma incidence in the immediate post-treatment interval. The terms subcritical (Reffective<1), MDA-subcritical (Reffective>1–<1.6) and supercritical (Reffective>1.6) refer to conditions in which infection is expected to be self-limited, requires annual MDA in order for control targets to be achieved or requires a new paradigm of treatment for eventual control, respectively. The different categories of transmission are demarcated by vertical black lines. Although our focus is on how the COVID-19 pandemic impacts trachoma control, the underlying model can be applied to a variety of diseases and program delay scenarios. For the subcritical and MDA-subcritical scenarios depicted in Figure 2 with a 1-y MDA disruption occurring at year 1.0, our estimate for the control delay is 0.85 and 2.02 y, respectively. The control delay is not calculable for the supercritical scenario because control is not expected to be achieved with annual MDA.

Update of

References

    1. World Health Organization . Validation of elimination of trachoma as a public health problem. Available from: http://www.who.int/trachoma/resources/who_htm_ntd_2016.8/en/ [accessed 6 November2020].
    1. Thylefors B, Dawson CR, Jones BRet al. . A simple system for the assessment of trachoma and its complications. Bull World Health Org. 1987;65(4):477–83. - PMC - PubMed
    1. World Health Organization Alliance for the Global Elimination of Trachoma. Report of the third meeting of the WHO Alliance for the Global Elimination of Trachoma, Ouarzazate, Morocco, 19–20 October 1998. Available from: https://apps.who.int/iris/handle/10665/65933 [accessed 29 June 2020].
    1. Hadfield J, Harris SR, Seth-Smith HMBet al. . Comprehensive global genome dynamics of Chlamydia trachomatis show ancient diversification followed by contemporary mixing and recent lineage expansion. Genome Res. 2017;27(7):1220–9. - PMC - PubMed
    1. Mabey DC, Solomon AW, Foster A. Trachoma. Lancet. 2003;362(9379):223–9. - PubMed

Publication types

Full text links
Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Cite

AltStyle によって変換されたページ (->オリジナル) /